Neurocrine Biosciences, Inc.

Good day, everyone, and welcome to today's Neurocrine Biosciences Report's first quarter results. At this time, all participants are in a listen-only mode. Later, you will have an opportunity to ask questions during the question-and-answer session. You may register to ask a question at any time by pressing the star and 1 on your touch-tone phone. Please note this call may be recorded, and I will be standing by should you need any assistance. It is now my pleasure to turn today's program over to Todd Tushla, VP of Investor Relations.

Thank you, operator. Good morning, everyone, and thanks for joining our first quarter 2022 earnings call. With me, as usual, are Kevin Gorman, our chief executive officer, Matt Abernethy, our chief financial officer, Eiry Roberts, our chief medical officer, Eric Benevich, our chief commercial officer, and Kyle Gano, our chief business development and strategy officer. Before we get going, I'll remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filing. After our prepared remarks, we'll be happy to address your questions. Now, I'll hand the call over to Kevin Gorman.

Thank you, Todd. Good morning, everyone. I'm sure you saw our press release this morning, and I have to say I'm very pleased with the work of our entire commercial and medical organization. in educating healthcare professionals on TD resulted in a record number of TD sufferers being treated with ingressa last quarter. Now, while the external environment has improved, it is not back to normal, and there are still challenges. However, I believe we are adapting well to the remote delivery of healthcare, which we know will persist at some level moving forward. So we have now seen our fourth consecutive quarter of sequential growth. We're not only making progress in our commercial business. As you may recall, at the beginning of the year, we updated you on the portfolio of clinical programs that we have started, what we are anticipating starting this year, and the data readouts. It was very aggressive. I'm pleased that we remain on track for most of these programs, importantly, including filing the SNDA for Ingresa in Huntington's disease and our two data readouts in essential tremor and CSWS. Now, as I will share with you, there are two programs that have been impacted by the invasion of Ukraine, and we are currently mitigating the impact of the loss of those potential clinical sites. But aside from that, We have handled this growing and complex pipeline extremely well, and I'm looking forward to sharing data with you later this year. With that, I'd like to hand it over to Matt, please.